Anzeige
Mehr »
Login
Donnerstag, 09.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
291 Leser
Artikel bewerten:
(1)

Rights and Issues Investment Trust PLC: RTE-Result of Tender Offer REPLACEMENT

Finanznachrichten News

DJ Rights and Issues Investment Trust PLC: RTE-Result of Tender Offer REPLACEMENT

Rights and Issues Investment Trust PLC (RIII) Rights and Issues Investment Trust PLC: RTE-Result of Tender Offer REPLACEMENT 28-Sep-2022 / 17:03 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

For immediate release 28 September 2022

RIGHTS AND ISSUES INVESTMENT TRUST PLC (the "Company")

RESULT OF TENDER OFFER - REPLACEMENT

The 'Result of Tender' announcement released on 28 September 2022 at 11:19 under EQS News ID '1452231' was incorrect and should be disregarded. The correct announcement is set out below.

Result of Tender O?er

The latest time for acceptance of the Tender Offer was 1.00 p.m. on 23 September 2022. 2,542,908 Ordinary Shares (representing approximately 36.2 per cent. of the Ordinary Shares outstanding on 27 September 2022) were validly tendered of which 528,101 Ordinary Shares were in respect of Basic Entitlements and 2,014,807 Ordinary Shares were in respect of Excess Applications. As a result, subject to all terms and conditions of the Tender Offer as set out in Part IV of the Circular being met, all valid tenders will be satisfied in full up to the Basic Entitlement and, following application of the scale-back mechanism (as set out in the circular sent to shareholders on 1 September 2022 (the "Circular"), tenders in excess of the Basic Entitlement will be satisfied to the extent of approximately 8.9 per cent. of the excess Ordinary Shares tendered (each such satisfied entitlement being rounded down to the nearest whole number of Ordinary Shares). Accordingly, upon the Tender Offer becoming unconditional, 706,904 Ordinary Shares will be purchased at the Tender Price, as determined in accordance with the terms and conditions of the Tender Offer as set out in Part IV of the Circular.

The Tender Price has been set at 2137.6434 pence per share, having been calculated in accordance with the terms and conditions of the Tender Offer as set out in the Circular.

As set out in the Circular, upon the Tender Offer becoming unconditional, the Ordinary Shares in respect of which tenders have been accepted will be purchased by finnCap Limited ("finnCap") pursuant to the Tender Offer and the Company will buy-back such Ordinary Shares from finnCap for cancellation.

Shareholders are reminded that settlement of the Tender Offer remains subject to the terms and conditions of the Tender Offer being met, including but not limited to the condition that the Tender Offer is subject to the FCA not deciding to exercise any power so as to prevent the implementation of the Company's proposed appointment of JUTM as its AIFM within the period (including any extension) specified therefore in accordance with the UK AIFM Regulations.

Capitalised terms and expressions shall have the same meanings as those attributed to them in the Circular.

For further information please contact:

Enquiries:

finnCap Limited 
William Marle / George Dollemore - Corporate Finance +44 (0) 20 7220 0500 
Mark Whitfeld / Pauline Tribe - Sales         +44 (0) 20 7220 0500 
 
Maitland Administration Services Limited 
 
                           +44 (0) 1245 398950 
cosec@maitlandgroup.com 
 

-----------------------------------------------------------------------------------------------------------------------

ISIN:      GB0007392078 
Category Code: RTE 
TIDM:      RIII 
LEI Code:    2138002AWAM93Z6BP574 
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares 
Sequence No.:  191144 
EQS News ID:  1452505 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1452505&application_name=news

(END) Dow Jones Newswires

September 28, 2022 12:03 ET (16:03 GMT)

© 2022 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.